Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Conditional OK Might Be an Option for KM Biologics Jab: Komeito Lawmaker
February 9, 2022
- MHLW to Consider Conditional Approval for Shionogi COVID Pill: Minister
February 9, 2022
- MHLW Ordered Label Revisions for Emergency Contraceptive Levonorgestrel
February 8, 2022
- Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
- Japan to Speed Up Boosters to “1 Million Doses per Day” ASAP: PM
February 7, 2022
- Lilly’s Retevmo Clears PAFSC for Thyroid Cancer; Lenvima/Keytruda to Get RCC Indication
February 7, 2022
- Japan Receiving 90,000 Further Courses of MSD COVID-19 Pill Earlier than Scheduled
February 7, 2022
- FY2022 Drug Price Revision Rate at -6.69% on Pharma Spending Basis
February 4, 2022
- Pfizer’s COVID-19 Pill Up for PAFSC Review on Feb. 10
February 4, 2022
- 9 Drugs/6 APIs for Fertility Treatment to Be Listed in April; Generics Listing in June at the Earliest: Chuikyo
February 3, 2022
- Govt Panel Proposes Enhanced Pharma Supply Chain through Economic Security Bill
February 2, 2022
- MHLW Clarifies Position on Investigational Drug Info; No Generic Names Allowed on Companies’ Clinical Trial Websites
February 2, 2022
- DPO Opted Not to Apply 80% Pricing Rule for Vynmac for Clinical Benefits: Minutes
February 2, 2022
- MHLW OKs 115 More COVID-19 Vaccine Health Damage Claims
February 1, 2022
- Japan Finalizes Deal for Pfizer’s COVID-19 Pills, Eyes Approval by Mid-February
February 1, 2022
- Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
- MHLW Panel Holds Off Decision on Bayer’s CKD Med Kerendia
January 31, 2022
- Veklury Use in Mild COVID-19 Could Be Considered: MHLW
January 31, 2022
- MSD Moves Up Supply of 50000 Courses of Lagevrio to Japan
January 31, 2022
- Cost-Effectiveness Analysis Temporarily Halted for Zolgensma to Collect Long-Term Data
January 31, 2022
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…